Monopar Therapeutics (MNPR) EPS (Basic) (2017 - 2020)

Monopar Therapeutics' EPS (Basic) history spans 4 years, with the latest figure at -$0.19 for Q4 2020.

  • For Q4 2020, EPS (Basic) fell 58.33% year-over-year to -$0.19; the TTM value through Dec 2020 reached -$0.58, down 28.89%, while the annual FY2024 figure was -$4.11, 35.2% down from the prior year.
  • EPS (Basic) for Q4 2020 was -$0.19 at Monopar Therapeutics, down from -$0.15 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.04 in Q1 2017 and bottomed at -$1.68 in Q3 2017.
  • The 4-year median for EPS (Basic) is -$0.1 (2018), against an average of -$0.2.
  • The largest YoY upside for EPS (Basic) was 95.83% in 2018 against a maximum downside of 125.0% in 2018.
  • A 4-year view of EPS (Basic) shows it stood at -$0.1 in 2017, then dropped by 0.0% to -$0.1 in 2018, then fell by 20.0% to -$0.12 in 2019, then plummeted by 58.33% to -$0.19 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's EPS (Basic) are -$0.19 (Q4 2020), -$0.15 (Q3 2020), and -$0.14 (Q2 2020).